344 related articles for article (PubMed ID: 29484447)
1. Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.
Benetatos L; Vartholomatos G
Cell Mol Life Sci; 2018 Jun; 75(11):1999-2009. PubMed ID: 29484447
[TBL] [Abstract][Full Text] [Related]
2. [Epigenetic dysregulation in myelodysplastic syndromes].
Sashida G
Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
[TBL] [Abstract][Full Text] [Related]
3. On the potential role of DNMT1 in acute myeloid leukemia and myelodysplastic syndromes: not another mutated epigenetic driver.
Benetatos L; Vartholomatos G
Ann Hematol; 2016 Oct; 95(10):1571-82. PubMed ID: 26983918
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
Wong JJ; Lau KA; Pinello N; Rasko JE
Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
[TBL] [Abstract][Full Text] [Related]
5. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
6. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic changes in therapy-related MDS/AML.
Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC; Agosto-Peña J
Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
[TBL] [Abstract][Full Text] [Related]
9. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.
Ye Y; McDevitt MA; Guo M; Zhang W; Galm O; Gore SD; Karp JE; Maciejewski JP; Kowalski J; Tsai HL; Gondek LP; Tsai HC; Wang X; Hooker C; Smith BD; Carraway HE; Herman JG
Cancer Res; 2009 Nov; 69(21):8482-90. PubMed ID: 19826047
[TBL] [Abstract][Full Text] [Related]
10. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
Benetatos L; Dasoula A; Hatzimichael E; Syed N; Voukelatou M; Dranitsaris G; Bourantas KL; Crook T
Ann Hematol; 2011 Sep; 90(9):1037-45. PubMed ID: 21340720
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia.
Rüter B; Wijermans PW; Lübbert M
Int J Hematol; 2004 Aug; 80(2):128-35. PubMed ID: 15481440
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics of myelodysplastic syndromes.
Itzykson R; Fenaux P
Leukemia; 2014 Mar; 28(3):497-506. PubMed ID: 24247656
[TBL] [Abstract][Full Text] [Related]
14. Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.
Qu Y; Siggens L; Cordeddu L; Gaidzik VI; Karlsson K; Bullinger L; Döhner K; Ekwall K; Lehmann S; Lennartsson A
Blood; 2017 Feb; 129(7):e13-e25. PubMed ID: 28003272
[TBL] [Abstract][Full Text] [Related]
15. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia.
Roux B; Picou F; Debeissat C; Koubi M; Gallay N; Hirsch P; Ravalet N; Béné MC; Maigre M; Hunault M; Mosser J; Etcheverry A; Gyan E; Delhommeau F; Domenech J; Herault O
Cancer Gene Ther; 2022 Aug; 29(8-9):1263-1275. PubMed ID: 35194200
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
Cechova H; Lassuthova P; Novakova L; Belickova M; Stemberkova R; Jencik J; Stankova M; Hrabakova P; Pegova K; Zizkova H; Cermak J
Neoplasma; 2012; 59(2):168-74. PubMed ID: 22248274
[TBL] [Abstract][Full Text] [Related]
17. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
[TBL] [Abstract][Full Text] [Related]
18. A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.
Sugino N; Kawahara M; Tatsumi G; Kanai A; Matsui H; Yamamoto R; Nagai Y; Fujii S; Shimazu Y; Hishizawa M; Inaba T; Andoh A; Suzuki T; Takaori-Kondo A
Leukemia; 2017 Nov; 31(11):2303-2314. PubMed ID: 28210006
[TBL] [Abstract][Full Text] [Related]
19. A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy.
Lao Z; Ding LW; Sun QY; Jia L; Yan B; Ng AY; Capinpin SM; Wang R; Ying L; Chng WJ; Koeffler HP; Koh WP; Yuan JM; Yang H; Goh YT; Grigoropoulos N
Clin Cancer Res; 2024 May; 30(10):2170-2180. PubMed ID: 38437679
[TBL] [Abstract][Full Text] [Related]
20. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
Larsson CA; Cote G; Quintás-Cardama A
Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
